Abstract:Rationale To investigate whether the mutational landscape of circulating cell-free DNA (cfDNA) could predict and dynamically monitor the response to first-line platinum-based chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). Methods Eligible patients were included and blood samples were collected from a phase III trial. Both cfDNA fragments and fragmented genomic DNA were extracted for enrichment in a 1.15M size panel covering exon regions of 1,086 genes. Molecular mutational burden (MMB) was calculated to investigate the relationship between molecular features of cfDNA and response to chemotherapy. Results In total, 52 eligible cases were enrolled and their blood samples were prospectively collected at baseline, every cycle of chemotherapy and time of disease progression. At baseline, alterations of 17 genes were found. Patients with partial response (PR) had significantly lower baseline MMB of these genes than those patients with either stable disease (SD) (P = 0.0006) or progression disease (PD) (P = 0.0074). Further analysis revealed that the mutational landscape of cfDNA from pretreatment blood samples were distinctly different among patients with PR vs. SD/PD. For patients with baseline TP53 mutation, those with PR experienced a significant reduction in MMB whereas patients with SD or PD experienced an increase after two, three or four cycles of chemotherapy. Furthermore, patients with low MMB had superior response rate and significantly longer progression-free survival than those with high MMB. Conclusion This study indicated that the mutational landscape of cfDNA has potential clinical value to predict the therapeutic response to first-line platinum-based doublet chemotherapy in NSCLC patients. At the single gene level, dynamic change of molecular mutational burden of TP53 is valuable to monitor efficacy (and, therefore, might aid in early recognition of resistance and relapse) in patients harboring this mutation at baseline.

Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine

Pharmacogenomics of Platinum-Based Chemotherapy Sensitivity in NSCLC: Toward Precision Medicine.

The pharmacogenomics of platinum chemotherapy in non-small cell lung cancer

Pharmacogenomics of Platinum-Based Chemotherapy in NSCLC

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Pharmacogenomics for the Efficacy of Platinum-Based Chemotherapy: Old Drugs, New Integrated Perspective.

Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer

Meta-analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients.

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.

Pharmacogenomics of Platinum-Based Chemotherapy Response in Nsclc: A Genotyping Study and A Pooled Analysis

Pharmacogenomics of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: Focusing on DNA Repair Systems

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Pharmocogenomics for predicting drug response in NSCLC chemotherapy

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients

A pharmacogenetics study of platinum- based chemotherapy in lung cancer: <i>ABCG2</i> polymorphism and its genetic interaction with <i>SLC31A1</i> are associated with response and survival

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Relationship between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in advanced non-small cell lung cancer patients

Germline Genetic Variations in Drug Action Pathways Predict Clinical Outcomes in Advanced Lung Cancer Treated with Platinum-Based Chemotherapy

Genome-wide Examination of Genetic Variants Associated with Response to Platinum-Based Chemotherapy in Patients with Small-Cell Lung Cancer